These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 11444087)

  • 1. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
    Trémollieres FA; Pouilles JM; Ribot C
    Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
    Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.
    Hart DM; Farish E; Fletcher CD; Barnes JF; Hart H; Nolan D; Spowart K
    Osteoporos Int; 1998; 8(4):326-32. PubMed ID: 10024902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.
    Sornay-Rendu E; Garnero P; Munoz F; Duboeuf F; Delmas PD
    Bone; 2003 Jul; 33(1):159-66. PubMed ID: 12919711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
    Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with peri- and postmenopausal bone loss: does HRT prevent weight loss-related bone loss?
    Sirola J; Kröger H; Honkanen R; Sandini L; Tuppurainen M; Jurvelin JS; Saarikoski S
    Osteoporos Int; 2003 Jan; 14(1):27-33. PubMed ID: 12577182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
    Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR
    Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
    Arrenbrecht S; Boermans AJ
    Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
    J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
    Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
    Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
    Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.